Small molecule · Inhibitor of DNA-dependent protein kinase (PRKDC) · developed by EMD Serono Research & Development Institute
Phase 1Most advanced trial (none active)
What is Peposertib?
Peposertib is an orally bioavailable small-molecule inhibitor of DNA-dependent protein kinase (DNA-PK). It binds and inhibits DNA-PK, interfering with non-homologous end joining and blocking repair of DNA double-strand breaks caused by radiation or chemotherapy, with potential sensitizing effects on those treatments.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
MSC-2490484A, M-3814
Drug type
Small molecule
Targets
DNA-dependent protein kinase (PRKDC)
Mechanism
Inhibitor of DNA-dependent protein kinase (PRKDC)
Pathways
non-homologous end joining (NHEJ) DNA double-strand break repair
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.